Beverley Balkau1, Françoise Calvi-Gries2, Nick Freemantle3, Maya Vincent4, Valerie Pilorget4, Philip D Home5. 1. INSERM Centre for Research in Epidemiology and Population Health (CESP), U1018, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France; University Paris-Sud, URMS 1018, Villejuif, France. Electronic address: beverley.balkau@inserm.fr. 2. AtlanStat, Rezé, France. 3. University College London, UK. 4. Sanofi, Paris, France. 5. Newcastle University, Newcastle upon Tyne, UK.
Abstract
AIMS: To identify factors associated with glucose control, as measured by HbA1c over 4 years, in people with type 2 diabetes starting insulin therapy. METHODS: CREDIT, an observational cohort study, collected data semi-annually over 4 years, on people with type 2 diabetes starting any insulin, in 311 centres in 12 countries; 2803 people had data on HbA1c during follow-up. Multivariable backward regression analysis selected characteristics associated with glycaemic control from a limited number of candidate variables. RESULTS: Before starting insulin therapy, HbA1c was 9.3% (78 mmol/mol) and decreased to 7.6% (60 mmol/mol) after 1 year, and changed little after that. Insulin dose increased from 0.21 U/kg to 0.36 U/kg at 1 year, and then by 0.10 U/kg over the next 3 years. Body weight increased by 2.0 kg in the first year and increased little thereafter. Poorer glycaemic control over the 4 years was mainly determined by the HbA1c before starting therapy, after accounting for the other statistically significant associated variables in multivariable analysis: higher BMI, younger age, longer diabetes duration, more glucose-lowering drugs, using basal insulin alone, higher insulin dose and female sex. At 4 years, a higher current insulin dose was the characteristic most strongly associated with a higher concurrent HbA1c. CONCLUSIONS: HbA1c at the start of insulin therapy was the characteristic most predictive of later HbA1c, after accounting for other variables associated with HbA1c. This may provide some justification for earlier insulin introduction to improve glucose control to target.
AIMS: To identify factors associated with glucose control, as measured by HbA1c over 4 years, in people with type 2 diabetes starting insulin therapy. METHODS: CREDIT, an observational cohort study, collected data semi-annually over 4 years, on people with type 2 diabetes starting any insulin, in 311 centres in 12 countries; 2803 people had data on HbA1c during follow-up. Multivariable backward regression analysis selected characteristics associated with glycaemic control from a limited number of candidate variables. RESULTS: Before starting insulin therapy, HbA1c was 9.3% (78 mmol/mol) and decreased to 7.6% (60 mmol/mol) after 1 year, and changed little after that. Insulin dose increased from 0.21 U/kg to 0.36 U/kg at 1 year, and then by 0.10 U/kg over the next 3 years. Body weight increased by 2.0 kg in the first year and increased little thereafter. Poorer glycaemic control over the 4 years was mainly determined by the HbA1c before starting therapy, after accounting for the other statistically significant associated variables in multivariable analysis: higher BMI, younger age, longer diabetes duration, more glucose-lowering drugs, using basal insulin alone, higher insulin dose and female sex. At 4 years, a higher current insulin dose was the characteristic most strongly associated with a higher concurrent HbA1c. CONCLUSIONS: HbA1c at the start of insulin therapy was the characteristic most predictive of later HbA1c, after accounting for other variables associated with HbA1c. This may provide some justification for earlier insulin introduction to improve glucose control to target.
Authors: Oliver Brown; Pierluigi Costanzo; Andrew L Clark; Gianluigi Condorelli; John G F Cleland; Thozhukat Sathyapalan; David Hepburn; Eric S Kilpatrick; Stephen L Atkin Journal: Cardiovasc Endocrinol Metab Date: 2020-05-25
Authors: David R Owens; Wolfgang Landgraf; Brian M Frier; Mei Zhang; Philip D Home; Luigi Meneghini; Geremia B Bolli Journal: Diabetes Obes Metab Date: 2019-02 Impact factor: 6.577
Authors: Keith Bowering; Helena W Rodbard; David Russell-Jones; Bruce Bode; Stewart Harris; Milivoj Piletic; Simon Heller; Vincent Woo; Vinay Babu; Claus Dethlefsen; Chantal Mathieu Journal: Diabetes Ther Date: 2018-12-13 Impact factor: 2.945
Authors: James F Graumlich; Huaping Wang; Anna Madison; Michael S Wolf; Darren Kaiser; Kumud Dahal; Daniel G Morrow Journal: J Diabetes Res Date: 2016-09-06 Impact factor: 4.011
Authors: Stephen M Twigg; Javier Escalada; Peter Stella; Ana Merino-Trigo; Fernando J Lavalle-Gonzalez; Bertrand Cariou; Luigi F Meneghini Journal: Diabetes Ther Date: 2018-09-10 Impact factor: 2.945